Internal Medicine · San Francisco, CA
NPI
1841364841
Since 2006
Specialty
Internal Medicine
Code 207R00000X
Group practices
0
Medicare group memberships
Hospitals
1
Hospital affiliations
818 Jackson St, Suite 101
San Francisco, CA, 94133
Phone (415) 956-9823
Medicare paid, 2024
$72K
781 services
Medicare patients, 2024
74
Average age 78
Drug cost, 2024
$1.2M
7,256 prescriptions
Company payments, 2025
$3,113
From 18 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Edward K Ko was code 99213 (office e&m - established), 322 times for 62 patients. In total Edward K Ko billed 781 services in 21 codes, and Medicare paid $72K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2020-10-13.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99213 Office E&M - Established | Office | 322 | 62 | $78.01 | $25K |
| 99214 Office E&M - Established | Office | 151 | 57 | $120.70 | $18K |
| G0439 Annual wellness visit, includes a personalized prevention plan of service (pps), subsequent visit | Office | 48 | 48 | $155.87 | $7,482 |
| G0008 Administration of influenza virus vaccine | Office | 43 | 42 | $38.68 | $1,663 |
| G0009 Administration of pneumococcal vaccine | Office | 40 | 40 | $38.68 | $1,547 |
| 90658 Vaccine Product | Office | 38 | 38 | $21.42 | $814 |
| 90732 Vaccine Product | Office | 35 | 35 | $130.80 | $4,578 |
| 99215 Office E&M - Established | Office | 21 | 18 | $168.44 | $3,537 |
| G0180 Physician or allowed practitioner certification for medicare-covered home health services under a home health plan of care (patient not present), including contacts with home health agency and review of reports of patient status required by physicians and | Office | 15 | 13 | $52.34 | $785 |
By year: 2022 $87K for 1,153 services; 2023 $75K for 876 services; 2024 $72K for 781 services.
Medicare prescription drug claims, 2024
In 2024, the drug Edward K Ko prescribed most often to Medicare patients was Atorvastatin Calcium, with 955 prescriptions and refills. In total Edward K Ko wrote 7,256 Medicare prescriptions that cost $1.2M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Atorvastatin Calcium Generic | 955 | 2,674 | 272 | $6,461 |
| Losartan Potassium Generic | 907 | 2,546 | 257 | $6,511 |
| Amlodipine Besylate Generic | 619 | 1,747 | 171 | $2,573 |
| Metoprolol Succinate Generic | 316 | 850 | 88 | $3,246 |
| Famotidine Generic | 309 | 857 | 107 | $2,351 |
| Triamcinolone Acetonide Generic | 284 | 317 | 113 | $3,361 |
| Farxiga Dapagliflozin Propanediol | 202 | 530 | 64 | $284K |
| Meclizine Hcl Generic | 195 | 236 | 72 | $3,320 |
| Jardiance Empagliflozin | 177 | 432 | 57 | $242K |
| Tamsulosin Hcl Generic | 159 | 458 | 47 | $1,481 |
| Allopurinol Generic | 157 | 434 | 46 | $1,141 |
| Pantoprazole Sodium Generic | 153 | 419 | 47 | $1,132 |
| Montelukast Sodium Generic | 139 | 383 | 56 | $1,145 |
| Isosorbide Mononitrate Er Isosorbide Mononitrate | 125 | 335 | 34 | $1,487 |
| Linzess Linaclotide | 120 | 306 | 54 | $155K |
Brand drugs: - claims; generic drugs: 5,716 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Edward K Ko $3,113 ($3,113 in general payments such as food, travel and fees) from 18 companies. The largest payer was AstraZeneca Pharmaceuticals LP with $554.
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP AZN | 14 | $554 |
| Amgen Inc. AMGN | 9 | $351 |
| Gilead Sciences, Inc. GILD | 6 | $328 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 9 | $200 |
| Novo Nordisk Inc NVO | 5 | $192 |
| Lilly USA, LLC LLY | 9 | $189 |
| Pfizer Inc. PFE | 3 | $162 |
| Janssen Biotech, Inc. JNJ | 1 | $144 |
| Merck Sharp & Dohme LLC MRK | 6 | $136 |
| Otsuka America Pharmaceutical, Inc. 4578.T | 1 | $124 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.